 "Dottikon Exclusive Synthesis' production facility")
Dottikon Exclusive Synthesis (ES) Group, which specialises in the area of hazardous reactions and manufactures active pharmaceutical ingredients (APIs) & fine chemicals, will invest more than CHF 100 million (about $101 million) in its development and production site in Dottikon (Aargau, Switzerland) over the coming two years. The major investments will consist of the creation of additional chemical process development and production capacities for APIs.
The new high-quality multi-tonne API drying capacities will be put into operation in the fourth quarter of 2016, while the additional multi-purpose production capacities for sophisticated chemistry will become operative in the first half of 2017. In order for the chemical process development and quality management to be ready for future growth, Dottikon ES will build a new four-storied laboratory and office building that will be ready in 2018.
Dottikon ES manufactures high-quality performance chemicals, intermediates and exclusive active pharmaceutical ingredients (APIs) for the global chemical and pharmaceutical industry. The company with its production site in Dottikon is specialised in hazardous reactions and is positioning itself as strategic development and manufacturing partner.
Its safety culture created over the last 100 years guides innovative use of hazardous reactions, low-temperature and high-pressure chemistry, as well as continuous processing. This shortens conventional chemical synthesis routes, increases yields & purities, and reduces waste. The versatile technology and equipment portfolio is used to design, develop and optimise chemical processes, and scale up from kilograms to multi-tonnes.
